Stay updated on Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.

Latest updates to the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe Record History now includes a new revision entry (Revision: v3.3.3) and removes the HHS Vulnerability Disclosure and the previous Revision: v3.3.2 entries. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check46 days agoChange DetectedA new revision entry v3.3.2 is added to the Record History and the previous revision v3.3.1 is removed from the listing. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedThe Record History now includes a new revision entry for v3.3.1, replacing v3.2.0, as part of standard page update activity. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedThe notice about government funding and NIH operating status was removed from the page, eliminating the maintenance alert. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check74 days agoChange DetectedVersions 2, 3, and 4 show updates to Study Status and Recruitment Status, reflecting the trial's progression and changes in recruitment.SummaryDifference0.1%

- Check103 days agoChange DetectedMajor change: page now includes a funding/status notice and a new v3.2.0 revision, replacing v3.0.2.SummaryDifference13%

Stay in the know with updates to Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Magrolimab + Azacitidine after Allo-HCT in High-Risk AML/MDS Clinical Trial page.